Human papillomavirus (HPV) vaccines have established efficacy in reducing invasive cervical cancer in females and have demonstrated protection against head and neck cancer (HNC) in males. The relationship between HPV vaccination in males and the subsequent risk of other potentially HPV-associated cancers and precursor lesions is less well described. This study used a large electronic health record–based research network to evaluate associations between HPV vaccination and a range of cancers and precancerous outcomes in males.
This investigation was a retrospective cohort study using the TriNetX United States Collaborative Network, a multi-institutional electronic health record database. Eligible subjects were males aged 9 to 45 years who did or did not receive HPV vaccination between 2006 and 2024. The vaccinated cohort size reported was 397,856 males.
Outcomes assessed included incidence of invasive cancers, carcinoma in situ, and precancerous lesions at anatomically relevant sites that have been considered potentially associated with HPV infection. Specifically, the analyses covered cancers and lesions of the penis, anus, head and neck (HNC), lung, esophagus, stomach, prostate, and colorectum. The study evaluated hazard ratios (HRs) comparing vaccinated and unvaccinated males for these outcomes.
The abstract does not report further cohort selection criteria, matching or adjustment variables, follow-up time, exact statistical models, or measures of absolute risk; those details were not reported in the source abstract.
Among males aged 9 to 45 within the TriNetX network, those who received HPV vaccination (n = 397,856) showed a lower hazard ratio for head and neck cancer compared with unvaccinated males. In addition to the reduction in HNC risk, vaccinated males had lower HRs for several other cancers reported in the abstract, including lung cancer, prostate cancer, and colorectal cancer.
The vaccinated group was also less likely to develop certain precancerous lesions and carcinoma in situ. The abstract specifically lists reduced incidence of precancerous lesions of the anus, head and neck, esophagus, and stomach among vaccinated males.
The abstract presents these associations as statistically significant without providing specific HR estimates, confidence intervals, or p-values in the summary. Details about absolute event counts, subgroup analyses (for example by age band or vaccine type), latency between vaccination and outcome, or sensitivity analyses were not reported in the abstract.
Using a large, real-world electronic health record platform, the authors observed associations between male HPV vaccination and lower risk of several cancers and precursor lesions beyond the previously established protective effect against HNC. The reported declines in incidence encompassed both head and neck malignancies and other malignancies such as lung, prostate, and colorectal cancer, as well as reductions in selected premalignant lesions at multiple anatomic sites.
These findings suggest potential broader benefits of HPV vaccination in males, but the mechanisms underlying protection against non-classical HPV-associated sites (for example lung or prostate) are not described in the abstract and warrant further investigation. The observational and retrospective design implies potential for residual confounding, selection bias, or misclassification that are not detailed in the abstract. Important methodological information—such as how vaccinated and unvaccinated cohorts were balanced, which covariates were controlled for, how outcomes were defined and validated, and length of follow-up—is not provided in the abstract and therefore cannot be evaluated here.
Further research is needed to confirm causality, to clarify biologic mechanisms, and to determine whether findings are consistent across different populations, vaccine types, dosing schedules, and longer follow-up periods.
In this TriNetX-based retrospective cohort of males aged 9–45 years, HPV vaccination was associated with significant reductions in risk for head and neck cancer and showed lower hazard ratios for several other cancers including lung, prostate, and colorectal cancers. Vaccinated males also had reduced incidence of selected precancerous lesions of the anus, head and neck, esophagus, and stomach. The authors call for further studies to evaluate protective mechanisms and to validate these associations.
The authors declared that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Note: The abstract provides study design, data source, cohort size for vaccinated males, cancer sites assessed, and main associations observed. Specific numerical effect estimates, confidence intervals, adjustment variables, follow-up duration, and other detailed methods or subgroup results were not reported in the abstract and are therefore not included here.